MYX Share Price Performance
AU$0
-5.21 (-100.00%)
Price AU$0
Fair ValueAU$4.62
Share Pricen/a
New Narrative • Jul 02
Mayne Pharma Group Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
MYX Community Narratives
AN
Fair Value
·Fair Value AU$4.62 38.0% undervalued intrinsic discount
Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value AU$3.83 25.3% undervalued intrinsic discount
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Women’s Health Trends And Dermatology Platform Will Reshape Long-Term Earnings Profile
Mayne Pharma is leaning into women’s health and branded dermatology as changing prescriptions and insurance coverage make it easier for patients to get its products. The bigger question is whether those tailwinds can turn into real profit as competition, rising costs, and one-off charges threaten to hold earnings back.Read more
AN
AU$4.62
38.0% undervalued intrinsic discount
Fair Value
Profit Margin
11.17%
Future PE
10.05x
Price in 2029
AU$5.64
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
Mayne Pharma’s women’s health brands are seeing strong prescription demand, but reported sales and profits don’t yet reflect it because returns, pricing adjustments, and heavy spending keep getting in the way. If those temporary drags ease while manufacturing and international expansion start to pay off, the business could look meaningfully stronger than today—though rising costs, legal bills, and new competition could delay that turnaround.Read more
AN
AU$3.83
25.3% undervalued intrinsic discount
Fair Value
Profit Margin
25.21%
Future PE
3.73x
Price in 2029
AU$4.69
Trending Discussion
Recently Updated Narratives
AN
Rising Women's Health Costs And Flat Revenue Will Eventually Reveal Underappreciated Earnings Potential
Fair Value: AU$3.83 25.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
None
Fair Value: AU$4.62 38.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Mayne Pharma Group Limited Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.01
- 62.64%
- -20.19%
- 10.5%
About MYX
- Founded
- 2005
- Employees
- 491
- CEO
- WebsiteView website
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Recent MYX News & Updates
Narrative Update • Jul 02
